Most companies need to de-risk early stage R&D.

How to do this when the number of opportunities for new R&D approaches has never been larger?

Whole institutes now specialise in pproaches that only twenty years ago barely existed. No company can provide equivalent expertise in-house with such

Our expertise can help:

  1. avoid the cost of buying in new, complex technologies.

  2. remove lag-times associated with training staff in new methods to achieve  only an elementary understanding.

life science consultancy

Assistance for

pharma & biotech

  1. reduce the number of experiments required to reach a stop/go decision.

  1. manage the selection and out-sourcing of non-core expertise

  2. select the appropriate insourcing of domain specialists